

Part nomenclature	Part No. (P/N)	Inspect per engine manual chapter
For CF6-80E1 Engines: Disk, Fan Rotor, Stage One	All	Sub Task 72-21-03-230-051 Fluorescent-Penetrant Inspection, and Sub Task 72-21-03-250-051 or 72-21-03-250-052 Disk Bore Eddy Current Inspection.
Shaft, Fan Forward	All	Sub Task 72-21-05-230-051 Fluorescent-Penetrant Inspection, and Sub Task 72-21-05-250-051 Vent Hole Eddy Current Inspection.
Compressor Rotor, Stage 1 Disk	All	Sub Task 72-31-04-230-051 Fluorescent-Penetrant Inspection.
Compressor Rotor, Stage 2 Disk	All	Sub Task 72-31-05-230-051 Fluorescent-Penetrant Inspection.
Compressor Rotor, Stage 3-9 Spool	All	Sub Task 72-31-06-230-051 Fluorescent-Penetrant Inspection.
Compressor Rotor, Stage 10 Disk (Pre SB 72-0150).	All	Sub Task 72-31-07-230-051 Fluorescent-Penetrant Inspection.
Compressor Rotor, Spool/Shaft, Stage 11-14 (Pre SB 72-0150).	All	Sub Task 72-31-08-230-051 Fluorescent-Penetrant Inspection
Compressor Rotor, Spool/Shaft, Stage 10-14 (SB 72-0150).	All	Sub Task 72-31-23-230-052 Fluorescent-Penetrant Inspection.
Compressor Rotor, No. 4 Bearing Rotating Air Seal (CDP Rotating Seal).	All	Sub Task 72-31-10-230-051 Fluorescent-Penetrant Inspection.
HPT Disk/Shaft, Stage 1	All	Sub Task 72-53-02-230-051 Fluorescent-Penetrant Inspection, and Sub Task 72-53-02-250-051 Eddy Current Inspection, Rim Bolt Holes, and Sub Task 72-53-02-250-054 Eddy Current Inspection, Disk Bore Area.
HPT Disk, Stage 2	All	Sub Task 72-53-06-230-051 Fluorescent-Penetrant Inspection, and Sub Task 72-53-06-250-051 Eddy Current Inspection, Rim Bolt Holes, and Sub Task 72-53-06-250-054 Eddy Current Inspection, Disk Bore Area.
LPT Rotor Shaft	All	Sub Task 72-55-01-240-051 Magnetic Particle Inspect.
LPT Disks, Stages 1-5	All	Sub Task 72-57-02-230-051 Fluorescent-Penetrant Inspect.
LPT Rotor Torque Cone	All	Sub Task 72-57-03-220-051 Fluorescent-Penetrant Inspect
For CF6-80E1 Engines configured with the R88DT Turbine: Disk Shaft, HPT Rotor	All	Sub Task 72-53-16-230-052 Fluorescent-Penetrant Inspect, and Sub Task 72-53-16-250-051 Disk Bore Area Eddy Current Inspection.
Disk, HPT Rotor, Stage 2 (R88DT, No Rim Bolt Holes).	All	Sub Task 72-53-18-230-051 Fluorescent-Penetrant Inspect, and Sub Task 72-53-18-250-051 Disk Bore Area Eddy Current Inspection.
HPT Rotor Rotating Interstage Seal (R88DT).	All	Sub Task 72-53-17-230-051 Fluorescent-Penetrant Inspect, and Sub Task 72-53-17-250-051 Seal Bore Area Eddy Current.
HPT Rotor Forward Outer Seal (R88DT)	All	Sub Task 72-53-21-230-051 Fluorescent-Penetrant Inspect, and Sub Task 72-53-21-250-051 Seal Bore Area Eddy Current.

(2) For the purposes of these mandatory inspections, piece-part opportunity means:

(i) The part is considered completely disassembled when accomplished in accordance with the disassembly instructions in the manufacturer's engine manual; and

(ii) The part has accumulated more than 100 cycles-in-service since the last piece-part opportunity inspection, provided that the part was not damaged or related to the cause for its removal from the engine."

(b) Except as provided in paragraph (c) of this AD, and notwithstanding contrary provisions in section 43.16 of the Federal Aviation Regulations (14 CFR 43.16), these mandatory inspections shall be performed only in accordance with the Life Limits Section of the manufacturer's ICA.

Alternative Methods of Compliance

(c) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Engine Certification Office (ECO). Operators must submit their requests through an appropriate FAA Principal Maintenance Inspector (PMI), who may add comments and then send it to the ECO.

Note 2: Information concerning the existence of approved alternative methods of compliance with this airworthiness directive, if any, may be obtained from the ECO.

Continuous Airworthiness Maintenance Program

(d) FAA-certificated air carriers that have an approved continuous airworthiness maintenance program in accordance with the record keeping requirement of § 121.369 (c) of the Federal Aviation Regulations (14 CFR 121.369 (c)) of this chapter must maintain records of the mandatory inspections that result from revising the Life Limits Section of the Instructions for Continuous Airworthiness (ICA) and the air carrier's continuous airworthiness program. Alternately, certificated air carriers may establish an approved system of record retention that provides a method for preservation and retrieval of the maintenance records that include the inspections resulting from this AD, and include the policy and procedures for implementing this alternate method in the air carrier's maintenance manual required by § 121.369 (c) of the Federal Aviation Regulations (14 CFR 121.369 (c)); however, the alternate system must be accepted by the appropriate PMI and require the maintenance records be maintained either indefinitely or until the work is repeated. Records of the piece-part inspections are not required under § 121.380 (a) (2) (vi) of the Federal Aviation Regulations (14 CFR 121.380 (a) (2) (vi)). All other Operators must maintain the records of mandatory inspections required by the applicable regulations governing their operations.

Note 3: The requirements of this AD have been met when the engine manual changes are made and air carriers have modified their continuous airworthiness maintenance plans to reflect the requirements in the engine manuals.

Effective Date

(e) This amendment becomes effective on May 15, 2002.

Issued in Burlington, Massachusetts, on April 3, 2002.

Jay J. Pardee,

Manager, Engine and Propeller Directorate, Aircraft Certification Service.

[FR Doc. 02-8641 Filed 4-9-02; 8:45 am]

BILLING CODE 4910-13-U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 522

Implantation or Injectable Dosage Form New Animal Drugs; Ketamine Hydrochloride

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original abbreviated new animal drug application (ANADA) filed by Vetrepharm Research, Inc. The ANADA provides for veterinary prescription use of an injectable solution of ketamine hydrochloride in cats and subhuman primates.

DATES: This rule is effective April 10, 2002.

FOR FURTHER INFORMATION CONTACT:

Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

SUPPLEMENTARY INFORMATION:

Vetrepharm Research, Inc., 119 Rowe Rd., Athens, GA 30601, filed ANADA 200-257 that provides for veterinary prescription use of Ketamine HCL, an injectable solution of ketamine hydrochloride, in cats and subhuman primates for restraint.

ANADA 200-257 is approved as of November 9, 2001, and the regulations are amended in 21 CFR 522.1222a to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In addition, Vetrepharm Research, Inc., has not been previously listed in

the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for this sponsor.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects*21 CFR Part 510*

Administrative practice and procedure, Animal drugs, Labeling,

Reporting and recordkeeping requirements.

21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding an entry for "Vetrepharm Research, Inc." and in the table in paragraph (c)(2) by numerically adding an entry for "064847" to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

*	*	*	*	*	*
(c)	*	*	*		
(1)	*	*	*		

Firm name and address	Drug labeler code
* * * * *	* *
Vetrepharm Research, Inc., 119 Rowe Rd., Athens, GA 30601	064847
* * * * *	* *

(2) * * *

Drug labeler code	Firm name and address
* * * * *	* *
064847	Vetrepharm Research, Inc., 119 Rowe Rd., Athens, GA 30601
* * * * *	* *

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

4. Section 522.1222a is revised to read as follows:

§ 522.1222a Ketamine.

(a) *Specifications.* Each milliliter contains ketamine hydrochloride equivalent to 100 milligrams (mg) ketamine base activity.

(b) *Sponsors.* See Nos. 000010, 000074, 000856, 059130, 061690, 064408, and 064847 in § 510.600(c) of this chapter.

(c) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) *Conditions of use—(1) Cats—(i) Amount.* 5 to 15 mg/pound body weight intramuscularly, depending on the effect desired.

(ii) *Indications for use.* For restraint or as the sole anesthetic agent in diagnostic or minor, brief surgical procedures that

do not require skeletal muscle relaxation.

(2) *Subhuman primates*—(i) *Amount*. 3 to 15 mg/kilogram body weight intramuscularly, depending upon the species, general condition, and age of the subject.

(ii) *Indications for use*. For restraint.

Dated: February 27, 2002.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 02-8569 Filed 4-9-02; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Lincomycin Hydrochloride Soluble Powder

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pharmacia and Upjohn Co. The supplemental NADA provides for the use of lincomycin hydrochloride soluble powder in the drinking water of swine weighing greater than 250 pounds for the treatment of swine dysentery.

DATES: This rule is effective April 10, 2002.

FOR FURTHER INFORMATION CONTACT:

Janis R. Messenheimer, Center for Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7578, e-mail: jmessenh@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Pharmacia and Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001-0199, filed a supplement to NADA 111-636 that provides for use of LINCOMIX (lincomycin hydrochloride) Soluble Powder for making medicated drinking water for the management of various bacterial diseases of swine and chickens. The supplemental NADA provides for replacement of the limitation "Not for use in swine weighing more than 250 pounds" with "The safety of lincomycin has not been demonstrated for pregnant swine or swine intended for breeding." The supplemental application is approved as of December 31, 2001, and the regulations are amended in 21 CFR

520.1263c to reflect the approval. Section 520.1263c is also being revised to reflect current editorial format.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this supplemental application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

2. Section 520.1263c is amended by revising paragraphs (a), (b), and (d) to read as follows:

§ 520.1263c Lincomycin hydrochloride soluble powder.

(a) *Specifications*. Each gram of soluble powder contains lincomycin hydrochloride equivalent to 0.4 grams of lincomycin.

(b) *Sponsors*. See Nos. 000009, 046573, and 051259 in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

* * * * *

(d) *Conditions of use*—(1) *Swine*—(i) *Amount*. 250 milligrams per gallon of drinking water to provide 3.8 milligrams per pound of body weight per day.

(ii) *Indications for use*. For the treatment of swine dysentery (bloody scours).

(iii) *Limitations*. Discard medicated drinking water if not used within 2

days. Prepare fresh stock solution daily. Do not use for more than 10 days. If clinical signs of disease have not improved within 6 days, discontinue treatment and reevaluate diagnosis. The safety of lincomycin has not been demonstrated in pregnant swine or swine intended for breeding.

(2) *Chickens*—(i) *Amount*. 64 milligrams per gallon of drinking water.

(ii) *Indications for use*. For the control of necrotic enteritis caused by *Clostridium perfringens* susceptible to lincomycin in broiler chickens.

(iii) *Limitations*. Discard medicated drinking water if not used within 2 days. Prepare fresh stock solution daily. Administer for 7 consecutive days. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to water containing lincomycin. Not for use in layer and breeder chickens.

Dated: March 25, 2002.

Andrew J. Beaulieu,

Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 02-8570 Filed 4-9-02; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 165

[CGD01-02-039]

RIN 2115-AA97

Safety Zone; Patriots Weekend, Dockside Restaurant Fireworks Display, Port Jefferson, NY

AGENCY: Coast Guard, DOT.

ACTION: Temporary final rule.

SUMMARY: The Coast Guard is establishing a temporary safety zone for a fireworks display located in Port Jefferson Harbor, Port Jefferson, NY. This action is necessary to provide for the safety of life on navigable waters during the event. This action is intended to restrict vessel traffic in a portion of Port Jefferson Harbor.

DATES: This rule is effective from 9:15 p.m. on June 8, 2002, until 10:15 p.m. on June 9, 2002.

ADDRESSES: Documents indicated in this preamble as being available in the docket, are part of docket (CGD01-02-039) and are available for inspection or copying at Coast Guard Group/Marine Safety Office, 120 Woodward Ave., New Haven, CT 06512, between 7:30 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Boatswain's Mate Second Class (BM2)